Search - tctmd.com

Displaying 21 - 40 of 296

Sort: Relevancy | Date

News Daily News

RECOVER IV Impella Trial Halted in the Wake of DanGer Shock

Caitlin E. Cox

June 18, 2024

Presentation NY Valves 2024

Histopathology From Explanted Valves in Patients With HALT and RLM

Presenter: Stephanie Sellers

June 07, 2024

Presentation NY Valves 2024

Halt is Not Relevant

Presenter: Stephan Windecker

June 06, 2024

Presentation NY Valves 2024

Halt is Relevant

Presenter: Raj Makkar

June 06, 2024

Presentation NY Valves 2024

Decrease in EOA as a Marker of Early HALT Detection Post Aortic Valve Replacement

Presenter: Pedro Covas

June 06, 2024

News Daily News

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

L.A. McKeown

April 24, 2024

News Daily News

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Michael O'Riordan

April 04, 2024

News Daily News

Semaglutide Winning Streak Continues in CKD With FLOW

Shelley Wood

March 06, 2024

News Daily News

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

L.A. McKeown

February 13, 2024

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

L.A. McKeown

November 20, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

L.A. McKeown

November 12, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

Presentation TCT 2023

Leaflet Thrombosis and HALT: The Achilles Heel of TTVR?

Presenter: Rahul Sharma

October 26, 2023

Presentation TCT 2023

TCT 732: Bridging Morphology and Flow: Exploring Their interplay in HALT Progression fFllowing TAVR Through CFD Analysis

Presenter: Thangam Natarajan

October 24, 2023

Presentation TCT 2023

TCT 588: Association of Prosthesis Deformation of Balloon-Expandable Transcatheter Aortic Valves With Subclinical Leaflet Thrombosis

Presenter: Shubhadarshini Pawar

October 24, 2023

Presentation TCT 2023

TCT 492: A Data-Driven Bayesian Model To Predict Leaflet Thrombosis After Bioprosthetic Aortic Valve Replacement

Presenter: Yousef Darestani

October 24, 2023

Presentation TCT 2023

TCT 258: Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Patients After Transcatheter Aortic Valve Implantation

Presenter: Daniel Overduin

October 24, 2023

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2023

Shelley Wood

October 03, 2023

News Daily News

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

L.A. McKeown

September 18, 2023

Presentation SCCT 2023

HALT – from Diagnosis to Prognosis

Presenter: Omar Khalique

July 28, 2023

Advertisement

RECOVER IV Impella Trial Halted in the Wake of DanGer Shock

Histopathology From Explanted Valves in Patients With HALT and RLM

Halt is Not Relevant

Halt is Relevant

Decrease in EOA as a Marker of Early HALT Detection Post Aortic Valve Replacement

BASIL-3: More Questions Than Answers About Drug-Coated Devices in CLTI

Climbing Everest? Cardiac Arrhythmias Join Other Fabled Risks

Semaglutide Winning Streak Continues in CKD With FLOW

Low Bleeding Profile With Asundexian Seen in Pooled Analysis

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

FDA Approves Paradise Renal Denervation System: What Comes Next?

Leaflet Thrombosis and HALT: The Achilles Heel of TTVR?

TCT 732: Bridging Morphology and Flow: Exploring Their interplay in HALT Progression fFllowing TAVR Through CFD Analysis

TCT 588: Association of Prosthesis Deformation of Balloon-Expandable Transcatheter Aortic Valves With Subclinical Leaflet Thrombosis

TCT 492: A Data-Driven Bayesian Model To Predict Leaflet Thrombosis After Bioprosthetic Aortic Valve Replacement

TCT 258: Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Patients After Transcatheter Aortic Valve Implantation

TCTMD’s Top 10 Most Popular Stories for September 2023

‘Overwhelming Reduction’ in Bleeding With Abelacimab vs Rivaroxaban in AF

HALT – from Diagnosis to Prognosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content